Atara Biotherapeutics, Inc. (ATRA) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -3.07M | -5.7M | -9.79M | -7.32M | -28.14M | -24.47M | -3.99M | -10.64M | -29.61M | -50.41M | -51.35M | -52.8M |
| Operating CF Margin % | -595.54% | -357.18% | -283.43% | -41.64% | -28.67% | -74.71% | -9.93% | -37.17% | -108.24% | -1185.47% | -2401.59% | -5516.82% |
| Operating CF Growth % | 89.08% | 76.72% | -145.35% | 31.25% | 4.98% | 51.45% | 92.23% | 79.84% | 22.94% | 11.38% | 21.08% | 17.46% |
| Net Income | -4.14M | -3.41M | -4.3M | 2.39M | 38.01M | -12.69M | -21.91M | -19.05M | -31.75M | -60.45M | -69.8M | -71.11M |
| Depreciation & Amortization | 29K | -126K | 36K | 236K | 1.79M | 1.1M | 1.23M | 1.33M | 1.39M | 1.21M | 1.21M | 1.2M |
| Stock-Based Compensation | 0 | 1.52M | 1.23M | 2.8M | 4.21M | 5.85M | 6.42M | 6.34M | 8.4M | 9.93M | 11.14M | 12.55M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.8M | 78.43M | 1.13M | 29K | 9.96M | 3.68M | 3.71M | 4.12M | 4.08M | 6.19M | 4.13M | 3.46M |
| Working Capital Changes | -754K | -82.11M | -7.88M | -12.77M | -82.11M | -22.41M | 6.56M | -3.38M | -11.73M | -7.28M | 1.97M | 1.09M |
| Change in Receivables | 1.25M | 660K | -1.91M | 8.88M | -7.39M | -147K | 1.09M | 33.41M | -1.73M | -33.95M | 344K | -110K |
| Change in Inventory | 0 | 0 | 0 | 0 | 10.65M | -160K | 4.77M | -2.67M | -6.38M | -3.12M | 1.27M | -2.52M |
| Change in Payables | 510K | -191K | -983K | -83K | -2.98M | 2.22M | -3.11M | 2.4M | -826K | -2.81M | 2.46M | -894K |
| Cash from Investing | 0 | 8.44M | -2.42M | -5.07M | 17.2M | 3.38M | -16.66M | 7.2M | 14.72M | 9.94M | 70.45M | 49.48M |
| Capital Expenditures | 0 | 0 | 0 | 349K | 0 | -90K | 0 | -29K | -127K | -44K | -281K | -499K |
| CapEx % of Revenue | - | - | - | 1.99% | - | 0.27% | - | 0.1% | 0.46% | 1.03% | 13.14% | 52.14% |
| Acquisitions | 0 | 0 | 44K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 555K | 0 | -5.42M | 0 | 0 | 0 | 0 | 0 | 0 | 25K | 0 |
| Cash from Financing | 2.95M | -3K | 1.05M | 15.3M | -250K | -328K | 35.79M | -324K | 24.14M | 1.51M | -208K | 471K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | -250K | -235K | -197K | -233K | -227K | -215K | -208K | -212K |
| Equity Issued (Net) | 2.95M | 0 | 1.03M | 0 | 0 | -210K | 50.81M | -15.03M | 24.37M | 1.55M | 0 | -50K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | -3K | 12K | 15.3M | 0 | 117K | -14.82M | 14.94M | -6K | 181K | 0 | 733K |
| Net Change in Cash | -122K | 2.74M | -11.16M | 2.92M | -11.19M | -21.42M | 15.14M | -3.77M | 9.25M | -38.95M | 18.89M | -2.84M |
| Free Cash Flow | -3.07M | -5.7M | -9.79M | -7.32M | -28.14M | -24.56M | -3.99M | -10.67M | -29.74M | -50.45M | -51.63M | -53.3M |
| FCF Margin % | -595.54% | -357.18% | -283.43% | -41.64% | -28.67% | -74.99% | -9.93% | -37.27% | -108.71% | -1186.5% | -2414.73% | -5568.97% |
| FCF Growth % | 89.08% | 76.8% | -145.35% | 31.44% | 5.38% | 51.32% | 92.27% | 79.97% | 23.41% | 11.36% | 20.8% | 18.49% |
| FCF per Share | -0.22 | -0.45 | -0.72 | -0.59 | -2.59 | -2.30 | -0.53 | -1.74 | -5.29 | -11.66 | -12.13 | -12.68 |
| FCF Conversion (FCF/Net Income) | 0.74x | 1.67x | 2.27x | -3.07x | -0.74x | 1.93x | 0.18x | 0.56x | 0.93x | 0.83x | 0.74x | 0.74x |
| Interest Paid | 0 | 0 | 53K | 52K | 66K | 188K | 138K | 245K | 114K | 115K | 114K | 106K |
| Taxes Paid | 0 | 0 | 28K | 3K | 0 | 0 | 0 | 0 | 24K | 0 | 0 | 1K |